-+ 0.00%
-+ 0.00%
-+ 0.00%

LANTERN PHARMA RECEIVES USPTO NOTICE OF ALLOWANCE FOR PATENT COVERING BIOMARKER-GUIDED TREATMENT WITH LP-184 (ZIRDAFULVEN) IN MULTIPLE SOLID TUMOR CANCERS

Reuters·07/23/2026 12:01:10

Please log in to view news